Clinical Trial Update: Gemcitabine Plus Docetaxel in Treating Patients With Unresectable or Metastatic Liver Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating gemcitabine plus docetaxel for unresectable or metastatic liver cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Gemzar (gemcitabine)
• Taxotere (docetaxel)

Snippet

Sponsor: Alliance for Clinical Trials in Oncology | Conditions: Liver Cancer | Phase 2 | Status: COMPLETED